申请人:——
公开号:US20040023978A1
公开(公告)日:2004-02-05
The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
本发明涉及4-[2-(5-氰基噻唑-2-基)氨基]吡啶-4-甲基-哌嗪-1-羧酸甲酰胺甲磺酸盐的口服活性盐形式,该盐形式能够抑制、调节和/或调节酪氨酸激酶信号传导,包含这些化合物的组合物,以及使用它们治疗哺乳动物的酪氨酸激酶依赖性疾病和病况的方法,例如血管生成、癌症、肿瘤生长、动脉硬化、老年性黄斑变性、糖尿病性视网膜病变、视网膜缺血、黄斑水肿、炎症性疾病等。